Detalhe da pesquisa
1.
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
BMC Cardiovasc Disord
; 19(1): 142, 2019 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31195999
2.
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
J Thromb Thrombolysis
; 48(2): 240-249, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30924051
3.
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Stroke
; 49(12): 2933-2944, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30571400
4.
Correction to: Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS Medicare population.
J Thromb Thrombolysis
; 51(2): 552-558, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32564179
5.
Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data.
Ann Pharmacother
; 47(7-8): 933-45, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23715066
6.
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
J Manag Care Spec Pharm
; 26(5): 639-651, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32347184
7.
Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus.
Mayo Clin Proc
; 95(5): 929-943, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32370854
8.
Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
Adv Ther
; 36(1): 162-174, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30499067
9.
Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.
PLoS One
; 14(3): e0213614, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30908512
10.
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
J Am Geriatr Soc
; 67(8): 1662-1671, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31112292
11.
Evaluating medication-related services in a hospital setting using the disconfirmation of expectations model of satisfaction.
Res Social Adm Pharm
; 4(1): 12-22, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18342819
12.
Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
J Manag Care Spec Pharm
; 24(11): 1116-1127, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30212268
13.
Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States.
Clin Appl Thromb Hemost
; 24(9_suppl): 261S-268S, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30433823
14.
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
J Manag Care Spec Pharm
; 24(9): 911-920, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-30156450
15.
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.
PLoS One
; 13(1): e0191722, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29373602
16.
Should I stay or should I go? The influence of individual and organizational factors on pharmacists' future work plans.
J Am Pharm Assoc (2003)
; 47(2): 165-73, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17510003
17.
Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics.
J Comp Eff Res
; 6(8): 659-669, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28791873
18.
Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents.
J Comp Eff Res
; 6(8): 671-682, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28791875
19.
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
J Med Econ
; 20(9): 952-961, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28604139
20.
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.
Thromb Haemost
; 117(6): 1072-1082, 2017 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28300870